MSB 1.04% $1.46 mesoblast limited

Ann: Phase 3 Trial in COVID-19 ARDS Surpasses 50% Enrollment, page-166

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 7,923 Posts.
    lightbulb Created with Sketch. 2084
    the trial should have taken weeks or less to enroll


    I was amazed at how quickly this trial was initially setup. There is an incredible amount of work in designing, organising and commencing trials, and made far more difficult in the midst of a pandemic.

    Perhaps if we knew the number of admitted persons at these sites that met the strict trial criteria, who were given the opportunity to participate in the agreed trial time frame, and the percentage of those (or their next of kin) that agreed to participate in the trial, we would be better placed to critique. Criticising trial progress without these facts is simply baseless commentary.

    I can think of myriad reasons that trial enrollment may have been slower than ideal. It doesn't affect my sentiment towards MSB.


 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.